Zacks Investment Research
17 Nov 2026, 00:50 UTC · 28m ago
MARKER THERAPEUTICS, INC. (MRKR) Reports Q3 Loss, Lags Revenue Estimates
Impact · against what's priced in
Marker Therapeutics' significant revenue miss outweighs its slight earnings beat, indicating continuing difficulty in scaling commercial growth. While the company continues to manage expenses effectively to beat EPS estimates, the 47% revenue miss remains the dominant negative catalyst.
- MRKR−0.30
No priced-in read yet
- In context
The company missed revenue estimates by 47.23% ($1.29 million actual), which offsets the modest earnings surprise of $0.10 loss versus $0.12 expected.
Read from the article alone

Search tags




